重组人升糖素(高血糖素)(胰高血糖素)(Glucagon)

特别提示：包括重组人升糖素(高血糖素)(胰高血糖素)(Glucagon)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人升糖素(高血糖素)(胰高血糖素)(Glucagon)
英文名称：Recombinant Human Glucagon
产品货号：JN0710
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Arg21-Lys180在C端含有His标签。

Glucagon质量控制：＞95%(还原性SDS-PAGE)

Glucagon制剂：液体

Glucagon保存：收到货后请置于-20℃，可保存6个月，避免反复冻融。

关于Glucagon：
Glucagon is a secreted protein and belongs to the glucagon family. Glucagon can be cleved into 8 chains, playing an important role in initiating and maintaining hyperglycemic conditions in diabetes. Glucagon can regulates blood glucose by decreasing glycolysis and increasing gluconeogenesis. In addition, Glucagon is involved in initiating and maintaining hyperglycemic conditions in diabetes. Glucagon release is stimulated by hypoglycemia and inhibited by hyperglycemia, insulin, and somatostatin. In the glucagon antagonist, His-53 and Phe-58 are missing. This antagonist has been successfully utilized to reduce glucose concentration in vivo.

除了重组人升糖素(高血糖素)(胰高血糖素)(Glucagon),，我公司还供应以下相关产品：



名称：重组人趋化因子CXCL2(MIP-2)
货号：JN0298
规格：10μg|50μg|500μg|1mg
本品由我们的大肠杆菌表达系统制备，目的基因编码的Thr39-Asn107表达纯化而来。

CXCL2/MIP-2质量控制：＞95%(还原性SDS-PAGE)。

CXCL2/MIP-2制剂：冻干品

CXCL2/MIP-2保存：
冻干蛋白可在-20℃长期保存，室温也可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天。
复溶后建议分装冻存在-20℃，可保存3个月，应避免反复冻融。

CXCL2/MIP-2复溶：
1、试剂开盖前请先离心。
2、复溶浓度应大于100 μg/ml.
3、冻干蛋白溶于ddH2O中
4、复溶后根据使用量分装保存，避免反复冻融。

关于CXCL2/MIP-2：
Chemokine Ligand 2 (CXCL2) is a small secreted cytokine which belongs to the CXC chemokine family. It is secreted by monocytes and macrophages and chemotactic for polymorphonuclear leukocytes and hematopoietic stem cells. CXCL2 mobilizes cells by interacting with a cell surface chemokine receptor called CXCR2. It has been known to regulate immune functions mainly by chemo-attracting neutrophils. It is produced by activated monocytes and neutrophils and expressed at sites of inflammation. It is a hematoregulatory chemokine, which suppresses hematopoietic progenitor cell proliferation. It can be induced by receptor activator of NF-kappaB ligand, the osteoclast (OC) differentiation factor, through JNK and NF-kappaB signaling pathways in OC precursor cells. CXCL2 in turn enhanced the proliferation of OC precursor cells of bone marrow-derived macrophages (BMMs) through the activation of ERK. Knockdown of CXCL2 inhibited both the proliferation of and the ERK activation in BMMs. During osteoclastogenesis CXCL2 stimulated the adhesion and the migration of BMMs. CXCL2 is a novel therapeutic target for inflammatory bone destructive diseases.